The central bank has suggested that states consider creating a capital expenditure buffer fund in good times and not treat capex as residual and the first stop for cutbacks.
Aarti Pharmalabs shares rally over 33% in two days post Q1 results. What is driving the surge?
Aarti Pharmalabs shares have surged 33% in two days after the company reported a 65.4% year-on-year rise in Q1FY27 profit and 38.7% growth in revenue.